Abstract
Recent evidence suggests that patients with chronic inflammatory disorders are at increased cardiovascular risk. A number of different mechanisms have been postulated to contribute to atherosclerotic disease progression in these patients including traditional cardiovascular risk factors, cytokine upregulation, immume mediated pathways and increased oxidative stress. Novel treatments target inflammatory pathways and have beneficial effect on rheumatic disease activity however; their impact on cardiovascular risk reduction remains unclear. Further longitudinal studies are required to assess the value of different therapeutic approaches on cardiovascular outcome of these patients.
Keywords: Inflammatory disorders, rheumatoid, lupus, drugs, antiphospholipid, cardiovascular risk, apoptosis, oxidative stress, atherosclerosis, cytokines
Current Pharmaceutical Design
Title: Inflammatory Disorders and Atherosclerosis: New Therapeutic Approaches
Volume: 17 Issue: 37
Author(s): Marietta Charakida, Frank O'Neil, Stefano Masi, Nikolaos Papageorgiou and Dimitris Tousoulis
Affiliation:
Keywords: Inflammatory disorders, rheumatoid, lupus, drugs, antiphospholipid, cardiovascular risk, apoptosis, oxidative stress, atherosclerosis, cytokines
Abstract: Recent evidence suggests that patients with chronic inflammatory disorders are at increased cardiovascular risk. A number of different mechanisms have been postulated to contribute to atherosclerotic disease progression in these patients including traditional cardiovascular risk factors, cytokine upregulation, immume mediated pathways and increased oxidative stress. Novel treatments target inflammatory pathways and have beneficial effect on rheumatic disease activity however; their impact on cardiovascular risk reduction remains unclear. Further longitudinal studies are required to assess the value of different therapeutic approaches on cardiovascular outcome of these patients.
Export Options
About this article
Cite this article as:
Charakida Marietta, O'Neil Frank, Masi Stefano, Papageorgiou Nikolaos and Tousoulis Dimitris, Inflammatory Disorders and Atherosclerosis: New Therapeutic Approaches, Current Pharmaceutical Design 2011; 17 (37) . https://dx.doi.org/10.2174/138161211798764807
DOI https://dx.doi.org/10.2174/138161211798764807 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
High Incidence of Infections in HIV-positive Patients Treated for Lymphoproliferative Disorders
Current HIV Research The Sirtuin Inhibitor Nicotinamide Enhances Neuronal Cell Survival During Acute Anoxic Injury Through AKT, BAD, PARP, and Mitochondrial Associated "Anti-Apoptotic" Pathways
Current Neurovascular Research Contribution of Dietary Factors to Peroxisome Proliferator-Activated Receptor-Mediated Inflammatory Signaling in Arthritic Diseases
Current Rheumatology Reviews Therapeutic Strategies to Reverse Local Bone Loss in Erosive Arthritis
Current Rheumatology Reviews Novel Approach to Treat Insulin Resistance, Type 2 Diabetes, and the Metabolic Syndrome: Simultaneous Activation of PPARα, PPARγ, and PPARδ
Current Diabetes Reviews Stem Cell Transplantation Improves Ovarian Function through Paracrine Mechanisms
Current Gene Therapy Recent Patents on Live Bacteria and their Products as Potential Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery The Role of the New Zealand Intensive Medicines Monitoring Programme in Identification of Previously Unrecognised Signals of Adverse Drug Reactions
Current Drug Safety Cerebrovascular Endothelin Receptor Upregulation in Cerebral Ischemia
Current Vascular Pharmacology Therapy Against Reperfusion-induced Microvascular Injury
Current Pharmaceutical Design Targeting Angiogenesis in Gastro-Intestinal Non Colorectal Cancers; A Review
Current Angiogenesis (Discontinued) Development of Agents that Modulate Protein-Protein Interactions in Membranes
Current Pharmaceutical Design Mechanisms Explaining the Influence of Subclinical Hypothyroidism on the Onset and Progression of Chronic Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets The Effects of Allergen and Anti-Allergic Drugs on Murine Hemopoietic Cells: Moving Targets, Unusual Mechanisms, and Changing Paradigms
Current Drug Targets - Inflammation & Allergy Melatonin Metabolism in the Central Nervous System
Current Neuropharmacology Cardiac (myo)fibroblast: Novel Strategies for its Targeting Following Myocardial Infarction
Current Pharmaceutical Design Effects of Statins on Bone Markers, Bone Mineral Density and Fractures. Possible Role in Osteoporosis Treatment
Current Pharmaceutical Analysis Neuroprotection Abilities of Cytosolic Phospholipase A2 Inhibitors in Kainic acid-induced Neurodegeneration
Current Drug Targets - Cardiovascular & Hematological Disorders Which Drugs for the Control of Fever in Critical Patients
Current Drug Targets Nanoparticles-Based Treatment for Bone Metastasis
Current Drug Targets